权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting Chronic ER Stress in T Cells to Improve Cancer Immunotherapy

针对 T 细胞中的慢性 ER 应激改善癌症免疫治疗

基本信息

批准号：
10625515
负责人：
Jessica E Thaxton
金额：
$ 34.56万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-01 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10625515
关键词：
Acute Acute-Phase Reaction Affect Animals Apoptotic CAR T cell therapy CD8-Positive T-Lymphocytes CD8B1 gene Cancer Patient Cell Death Cell Death Induction Cell physiology Cells Cellular biology Cessation of life Chronic Chronic stress Cytoprotection Data Development Endoplasmic Reticulum Enzymes Eukaryotic Initiation Factor-2 Exhibits Generations Genetic Genetic Transcription Human Immune system Immunotherapy Impairment Inflammatory Measures Memory Memory impairment Metabolic Metabolic Diseases Metabolic dysfunction Molecular Molecular Target Mus Mutant Strains Mice Oxidoreductase PF4 Gene Patients Phase Phenotype Phosphorylation Phosphotransferases Process Protein Kinase Proteins Reactive Oxygen Species Research Role Shapes Solid Neoplasm Stress T memory cell T-Lymphocyte Testing Toxic effect Translational Repression Translations Tumor Antigens Tumor Promotion Tumor-Infiltrating Lymphocytes Work activating transcription factor 4 acute stress anti-PD1 therapy arm attenuation biological adaptation to stress cancer immunotherapy checkpoint therapy drug development effector T cell endoplasmic reticulum stress exhaust exhaustion experience humanized mouse immunogenic improved in vivo innovation interest kinase inhibitor metabolomics mouse model overexpression programmed cell death protein 1 programs protein kinase R response sarcoma sensor success targeted treatment trait tumor tumor growth tumor microenvironment

项目摘要

PROJECT SUMMARY Sarcomas are an immunogenic tumor type replete with tumor antigen experienced CD8 tumor infiltrating lymphocytes (TILs). Surprisingly, checkpoint therapy that targets programmed cell death protein 1 (a-PD-1) to reinvigorate CD8 TILs is largely ineffective in sarcomas and has not gained FDA approval. CD8 TILs experience stress, but the stress response has not been widely studied in CD8 TILs of cancer patients. Under acute stress, endoplasmic reticulum (ER) stress sensor protein kinase R (PKR)-like ER kinase (PERK) protects cells. Under chronic stress, PERK activates a pro-apoptotic response that induces cell death. We previously demonstrated that PERK is detrimental to CD8 T cells in tumors. We now reveal robust preliminary data that indicate that the chronic PERK axis governed by activating transcription factor 4 (ATF4) and ER oxidoreductase 1 (ERO1a) shapes CD8 TIL fate in mouse and human sarcomas and impairs response to a-PD-1 therapy. Our data are intriguing given the role of PERK to protect cells under acute stress through attenuation of translation. Indeed, we found that the tumor microenvironment is a form of acute stress that inhibits translation in CD8 T cells through PERK. However, in vivo in the presence of tumor antigen, the chronic arm of the PERK response appears to dictate PD-1+ CD8 TIL fate. This proposal will formally test that chronic targets ATF4 and ERO1a drive activation and metabolic exhaustion in CD8 TILs that limit the efficacy of a-PD-1 therapy, while the acute PERK response protects CD8 TILs under sarcoma microenvironment stress. To accomplish our aims we have developed unique genetic mouse models to analyze the T cell-specific contributions of the chronic and acute phases of the stress response to shape efficacy of a-PD-1 therapy in sarcomas. In Aim 1, we will use LckcreRosa26-ATF4loxtg mice with T cell-specific overexpression of human ATF4 and CD8 TILs from sarcoma patients to determine the contribution of ATF4 to drive activation and exhaustion in CD8 TILs and shape response to a-PD-1 therapy in sarcomas. The results are expected to reframe and advance our understanding of T cell exhaustion in sarcomas. In Aim 2 we have created unique ERO1a-/- mice to formally define how ERO1a affects CD8 TIL metabolic exhaustion and response to a-PD-1 therapy and we will use CD8 TILs from sarcoma patients to study the contribution of ERO1a to human TIL exhaustion. The results are expected to produce a robust molecular target that holds fantastic potential to improve the efficacy of a-PD-1 therapy in cancer patients. In Aim 3 we will use our LckcrePERKf/f mice and Eif2aS51A mutant mice to elucidate requirements of the acute stress response in CD8 TILs. The results are expected to shape the direction of drug development surrounding the ER stress response in cancer immunotherapy. Successful completion of this proposal will identify radical new chronic ER stress targets that undermine the widespread success of immunotherapy in sarcoma patients and establish a new paradigm that informs drug development for all solid tumor cancer patients.

项目总结